Good morning :)
Place Order
Add to Watchlist

Lasa Supergenerics Ltd

LASA

Lasa Supergenerics Ltd

LASA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹123 cr, stock is ranked 2,857
High RiskStock is 3.85x as volatile as Nifty
24.700.37% (+0.09)
24.700.37% (+0.09)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹123 cr, stock is ranked 2,857
High RiskStock is 3.85x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹123 cr, stock is ranked 2,857
High RiskStock is 3.85x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-5.431.28
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.116.510.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lasa Supergenerics Limited is engaged in the manufacturing of anthelmintics/veterinary active pharmaceutical ingredient (API). The Company also manufactures bulk drugs

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -9.29%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.08% to 0.03%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue0.00200.92246.94170.04167.49202.44137.40131.37104.44121.66
Raw Materialssubtract0.00141.67172.06126.2187.01102.1194.46110.1279.28128.82
Power & Fuel Costsubtract6.036.646.717.928.067.067.727.45
Employee Costsubtract9.5510.2711.7413.4214.017.156.355.37
Selling & Administrative Expensessubtract2.244.454.656.549.729.036.985.64
Operating & Other expensessubtract19.938.789.1522.4121.1611.2624.8513.15
Depreciation/Amortizationsubtract0.007.6918.1719.3117.3415.8214.5113.4210.6710.94
Interest & Other Itemssubtract0.0011.6811.358.388.122.060.064.191.993.11
Taxes & Other Itemssubtract0.00-0.222.89-4.071.116.72-0.81-3.652.621.51
EPS0.00470.0010.76-5.271.145.60-1.17-7.71-4.34-4.53
DPS0.000.000.000.000.000.250.250.000.000.00
Payout ratio0.000.000.000.000.040.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2018

Annual report

PDF

Investor Presentation

May 29PDF
Feb 14PDF
Dec 13PDF
Dec 13PDF
FY 2020

Annual report

PDF

Investor Presentation

Jun 19PDF
FY 2021

Annual report

PDF

Investor Presentation

Oct 28PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Lasa Supergenerics Ltd-5.671.28
Sun Pharmaceutical Industries Ltd44.626.370.76%
Cipla Ltd30.064.620.85%
Torrent Pharmaceuticals Ltd67.9216.410.84%

Price Comparison

Compare LASA with any stock or ETF
Compare LASA with any stock or ETF
LASA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding53.65%0.00%0.00%0.01%46.34%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.01%0.12%0.00%0.01%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 16, 2022

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Sep 16, 2022

Cash Dividend

Ex DateEx DateSep 15, 2021

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Sep 15, 2021

News & Opinions
Earnings
Lasa Supergenerics reports standalone net loss of Rs 3.23 crore in the September 2024 quarter

Net Loss of Lasa Supergenerics reported to Rs 3.23 crore in the quarter ended September 2024 as against net loss of Rs 0.02 crore during the previous quarter ended September 2023. Sales rose 62.10% to Rs 39.39 crore in the quarter ended September 2024 as against Rs 24.30 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales39.3924.30 62 OPM %2.014.32 - PBDT1.500.57 163 PBT-1.31-2.11 38 NP-3.23-0.02 -16050 Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Lasa Supergenerics to conduct board meeting

Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Lasa Supergenerics AGM scheduled

Lasa Supergenerics announced that the 9th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Lasa Supergenerics reports standalone net loss of Rs 2.73 crore in the June 2024 quarter

Net Loss of Lasa Supergenerics reported to Rs 2.73 crore in the quarter ended June 2024 as against net loss of Rs 4.95 crore during the previous quarter ended June 2023. Sales rose 0.92% to Rs 30.84 crore in the quarter ended June 2024 as against Rs 30.56 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales30.8430.56 1 OPM %5.8413.25 - PBDT0.933.68 -75 PBT-1.861.03 PL NP-2.73-4.95 45 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Lasa Supergenerics schedules board meeting

Lasa Supergenerics will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Lasa Supergenerics reports standalone net loss of Rs 6.61 crore in the September 2022 quarter

2 years agoBusiness Standard

Lasa Supergenerics Ltd leads gainers in ‘B’ group

2 years agoBusiness Standard

Wardwizard Innovations & Mobility Ltd PartlyPaidup leads gainers in ‘B’ group

2 years agoBusiness Standard

Stocks that will see action on April 27, 2022

2 years agoThe Hindu Businessline

Lasa Supergenerics standalone net profit rises 223.16% in the March 2022 quarter

2 years agoBusiness Standard